Modification of alternative splicing by antisense therapeutics

被引:36
作者
Kole, R
Vacek, M
Williams, T
机构
[1] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA
关键词
D O I
10.1089/154545704322988067
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alternative splicing allows the production of several different proteins from a single pre-mRNA, resulting in an increased diversity of proteins derived from a relatively limited number of transcribed genes. Although it is necessary for normal development, alternative splicing and its aberrations are also implicated in disease states from thalassemia and cancer to neurodegenerative disorders. Techniques that trick the splicing machinery to alter the splicing pathways can be of high therapeutic value. Antisense technology, used mostly for RNA downregulation, recently has been adapted to alter the splicing process. The promise of this approach is now being realized as a result of chemical modification of oligonucleotides and improvements in their delivery in vivo.
引用
收藏
页码:65 / 74
页数:10
相关论文
共 61 条
[1]   Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: Effects on cellular uptake, binding to target sequences, and biologic actions [J].
Astriab-Fisher, A ;
Sergueev, D ;
Fisher, M ;
Shaw, BR ;
Juliano, RL .
PHARMACEUTICAL RESEARCH, 2002, 19 (06) :744-754
[2]   Mechanisms of alternative pre-messenger RNA splicing [J].
Black, DL .
ANNUAL REVIEW OF BIOCHEMISTRY, 2003, 72 :291-336
[3]   SR-related proteins and the processing of messenger RNA precursors [J].
Blencowe, BJ ;
Bowman, JAL ;
McCracken, S ;
Rosonina, E .
BIOCHEMISTRY AND CELL BIOLOGY, 1999, 77 (04) :277-291
[4]   Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases [J].
Blencowe, BJ .
TRENDS IN BIOCHEMICAL SCIENCES, 2000, 25 (03) :106-110
[5]   BCL-X, A BCL-2-RELATED GENE THAT FUNCTIONS AS A DOMINANT REGULATOR OF APOPTOTIC CELL-DEATH [J].
BOISE, LH ;
GONZALEZGARCIA, M ;
POSTEMA, CE ;
DING, LY ;
LINDSTEN, T ;
TURKA, LA ;
MAO, XH ;
NUNEZ, G ;
THOMPSON, CB .
CELL, 1993, 74 (04) :597-608
[6]   Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs [J].
Broome, HE ;
Yu, AL ;
Diccianni, M ;
Camitta, BM ;
Monia, BP ;
Dean, NM .
LEUKEMIA RESEARCH, 2002, 26 (03) :311-316
[7]  
Budker V, 1996, GENE THER, V3, P593
[8]   REGULATION OF ALTERNATIVE SPLICING IN-VIVO BY OVEREXPRESSION OF ANTAGONISTIC SPLICING FACTORS [J].
CACERES, JF ;
STAMM, S ;
HELFMAN, DM ;
KRAINER, AR .
SCIENCE, 1994, 265 (5179) :1706-1709
[9]   Listening to silence and understanding nonsense: Exonic mutations that affect splicing [J].
Cartegni, L ;
Chew, SL ;
Krainer, AR .
NATURE REVIEWS GENETICS, 2002, 3 (04) :285-298
[10]   Correction of disease-associated exon skipping by synthetic exon-specific activators [J].
Cartegni, L ;
Krainer, AR .
NATURE STRUCTURAL BIOLOGY, 2003, 10 (02) :120-125